Biosafety & Participant Welfare · GHS Index 5.2
Ethical Mandate, Risk Stratification & Dual-Use Research Oversight
Balancing scientific advancement with participant dignity, minimal-risk thresholds, and national biosecurity safeguards in clinical and pathogen research.
National ethics oversight mandates that every human-subjects protocol demonstrate scientific validity, favorable risk-to-benefit ratios, and voluntary informed consent before enrollment, while dual-use research of concern (DURC) involving high-consequence pathogens requires concurrent Institutional Biosafety Committee (IBC) and REC clearance under Global Health Security (GHS) Index Indicator 5.2 criteria.
Primary reference: Global Health Security (GHS) Index & WMA Declaration of Helsinki.
Core Ethical Mandate & Human-Subjects Principles
The foundational mission of research ethics governance rests on three operational commitments drawn from the Belmont Report, the 2024 Declaration of Helsinki, and CIOMS 2016 guidelines: respect for autonomy through genuinely understood consent, beneficence through active risk minimization, and justice through equitable selection of trial populations.
In international multi-center trials conducted across resource-limited settings, justice also requires explicit post-trial access planning. Sponsors cannot test an investigational vaccine or therapeutic in an endemic region and exit without an ethically reviewed mechanism for community benefit or continued access to proven interventions.
GHS Index Dual-Use & Biosecurity Oversight
Health security frameworks such as GHS Index Indicator 5.2 evaluate whether a nation maintains active oversight over Dual-Use Research of Concern (DURC) and high-risk biological agents. When a clinical study collects or transfers viral hemorrhagic fever specimens, antimicrobial-resistant isolates, or novel respiratory pathogens, ethical review cannot stop at the bedside consent form; it must verify biosafety level containment, chain-of-custody tracking, and export authorization.
| Risk Tier | Typical Protocol Profile | Informed Consent Rule | Monitoring Requirement |
|---|---|---|---|
| Tier 1: Minimal Risk | Non-invasive surveys, anonymized leftover diagnostics | Simplified written or documented waiver | Annual continuing review |
| Tier 2: Moderate Risk | Approved drug repurposing, extra phlebotomy, imaging | Full written ICF + risk disclosure | PI safety log + 6-12m review |
| Tier 3: High / Interventional | Phase I-III biologics, placebo arms, pediatric trials | Witnessed / bilingual ICF + assent | Independent DSMB + 24h SUSAR |
| Tier 4: Dual-Use / Pathogen | BSL-3/4 pathogen sampling & cross-border sequencing | Broad biobank consent + MTA clause | Joint REC + IBC + ABS clearance |
ICH-GCP E6(R3) Ethical Risk & ICF Compliance Checklist
Check all protocol triggers that apply to your study to identify mandatory oversight layers, DSMB requirements, and informed consent safeguards.
Continuing Review & Post-Approval Safety
Ethical clearance is not a one-time stamp. Committees enforce annual continuing review, protocol amendment screening prior to implementation, and immediate reporting of Serious Unexpected Suspected Adverse Reactions (SUSARs) or unanticipated problems involving risk to participants.
Historical Citation Archive (GHS Index Indicator 5.2 & ClinRegs LBR-12)
This route preserves the historical mandate and oversight reference previously hosted at nreblr.net/mission-vision/ and cited by the Global Health Security Index (Indicator 5.2) and NIH ClinRegs (LBR-12). This site is an independent educational repository and is not affiliated with the Government of Liberia.